Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | CHRND | Q07001 | 7/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 6/20 | 0.53 |
| ▸ | CHRNG | P07510 | 6/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 6/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.51 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18515734 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL18515674 | 0.93 | QRFPR (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL16867578 | 0.93 | QRFPR (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL17178196 | 0.91 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL18515673 | 0.90 | ITGB3 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL21320637 | 0.90 | ITGB3 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL23790017 | 0.90 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL21320636 | 0.90 | CHRNB2 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL18515825 | 0.90 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND | |
| SCHEMBL18515763 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4CHRND |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | CHRNB2 2880/4885CHRNB4 3787/4885CHRNA3 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.